New patent for ORLADEYO’s Biocryst drug – DrugPatentWatch
Annual Drug Patent Expiration for ORLADEYO
Orladeyo is a drug marketed by Biocryst and included in one NDA. It is available from a single supplier. There are six patents protecting this drug.
This drug has sixty-three patent family members in thirty-two countries.
The generic ingredient in ORLADEYO is otralstat hydrochloride. One registered supplier for this compound. Additional details are available on the otralstat hydrochloride profile page.
For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com
Make Better Decisions with DrugPatentWatch
» Start Your Free Trial Today «
Copyright © DrugPatentWatch. Originally published in New patent for the drug Biocryst ORLADEYO